GENINCODE PLC LS -01 Net Assets
GENINCODE PLC LS -01 net assets. Based on the latest financial reports, GENINCODE PLC LS -01 (9PL) has net assets worth €124.00K EUR (≈ $144.97K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.38 Million ≈ $2.78 Million USD) and total liabilities (€2.25 Million ≈ $2.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is GENINCODE PLC LS -01 growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €124.00K |
| % of Total Assets | 5.22% |
| Annual Growth Rate | -69.17% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.32 |
Net Assets of GENINCODE PLC LS -01 (2021–2025)
Net assets of GENINCODE PLC LS -01 from 2021 to 2025. This chart illustrates how GENINCODE PLC LS -01's net assets have evolved over time, based on quarterly financial data. See GENINCODE PLC LS -01 (9PL) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for GENINCODE PLC LS -01 (2021–2025)
The table below shows the annual net assets of GENINCODE PLC LS -01 from 2021 to 2025. For live market cap and overall valuation, see 9PL company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €124.00K ≈ $144.97K |
-89.00% |
| 2024-12-31 | €1.13 Million ≈ $1.32 Million |
-12.57% |
| 2023-12-31 | €1.29 Million ≈ $1.51 Million |
-83.68% |
| 2022-12-31 | €7.90 Million ≈ $9.24 Million |
-42.41% |
| 2021-12-31 | €13.72 Million ≈ $16.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GENINCODE PLC LS -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2271400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
GENINCODE PLC LS -01 Net Assets Breakdown (December 2025)
GENINCODE PLC LS -01 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €25.77 Million | 20785.48% |
| Total Equity | €124.00K | 100.00% |
GENINCODE PLC LS -01 Competitors by Market Cap
The table below lists competitors of GENINCODE PLC LS -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KST Beteiligungs AG
F:KSW
|
$5.28 Million |
|
UNIDOC HEALTH CORP.
F:L7T
|
$5.29 Million |
|
RKEC Projects Limited
NSE:RKEC
|
$5.30 Million |
|
K.C. Metalsheet Public Company Limited
BK:KCM
|
$5.30 Million |
|
Tennant Minerals Ltd
AU:TMS
|
$5.28 Million |
|
Envy Technologies Indonesia Tbk PT
JK:ENVY
|
$5.27 Million |
|
Dominion Minerals Ltd
AU:DLM
|
$5.27 Million |
|
Eng Kah Corporation Bhd
KLSE:7149
|
$5.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENINCODE PLC LS -01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,127,000 to 124,000, a change of -1,003,000 (-89.0%).
- Net loss of 5,705,000 reduced equity.
- New share issuances of 3,743,000 increased equity.
- Other factors increased equity by 959,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-5.71 Million | -4600.81% |
| Share Issuances | €3.74 Million | +3018.55% |
| Other Changes | €959.00K | +773.39% |
| Total Change | €- | -89.00% |
Book Value vs Market Value Analysis
This analysis compares GENINCODE PLC LS -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.04x to 13.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.14 | €0.01 | x |
| 2022-12-31 | €0.08 | €0.01 | x |
| 2023-12-31 | €0.01 | €0.01 | x |
| 2024-12-31 | €0.01 | €0.01 | x |
| 2025-12-31 | €0.00 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GENINCODE PLC LS -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4600.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -185.47%
- • Asset Turnover: 1.29x
- • Equity Multiplier: 19.17x
- Recent ROE (-4600.81%) is below the historical average (-1127.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -30.19% | -358.93% | 0.08x | 1.11x | €-5.51 Million |
| 2022 | -70.37% | -388.74% | 0.12x | 1.49x | €-6.35 Million |
| 2023 | -544.30% | -324.81% | 0.52x | 3.25x | €-7.14 Million |
| 2024 | -393.43% | -164.16% | 1.01x | 2.36x | €-4.55 Million |
| 2025 | -4600.81% | -185.47% | 1.29x | 19.17x | €-5.72 Million |
Industry Comparison
This section compares GENINCODE PLC LS -01's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,813,912,805
- Average return on equity (ROE) among peers: -36.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENINCODE PLC LS -01 (9PL) | €124.00K | -30.19% | 18.17x | $5.28 Million |
| IZOTROPIC CORP. (1R3) | $-3.85 Million | 0.00% | 0.00x | $6.11 Million |
| ALPHAHELIX MOL.DIAGN. SK1 (4MB) | $4.18 Million | -188.49% | 2.68x | $839.64K |
| HANGZHOU TIGERMED CO. H 1 (5HZ1) | $24.45 Billion | 8.28% | 0.21x | $604.57 Million |
| Check-Cap Ltd (7CC) | $16.38 Million | -84.54% | 0.20x | $9.20 Million |
| INTERGRATED DIA.H DL 025 (8I8) | $3.50 Billion | 30.79% | 1.04x | $251.46 Million |
| GENETIC ANALYSIS NK -60 (8V8) | $32.00 Million | -74.44% | 0.67x | $2.36 Million |
| INOVIQ LTD. (EGQ0) | $28.29 Million | -64.31% | 0.09x | $13.50 Million |
| Eurofins Scientific SE (ESF0) | $4.68 Billion | 16.73% | 1.00x | $11.18 Billion |
| ICON Public Limited Company (IJF) | $1.62 Billion | 23.11% | 0.80x | $7.52 Billion |
About GENINCODE PLC LS -01
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of fa… Read more